Terns Pharmaceuticals posts Q3 net loss of $24.6 million on R&D spending increase

Reuters

Nov 11

Terns Pharmaceuticals posts Q3 net loss of $24.6 million on R&D spending increase

Terns Pharmaceuticals Inc. reported a net loss of $24.6 million for the third quarter ended September 30, 2025, compared to a net loss of $21.9 million for the same period in 2024. Research and development expenses increased to $19.9 million from $15.2 million, while general and administrative expenses decreased to $7.8 million from $9.8 million year-over-year. As of September 30, 2025, cash, cash equivalents, and marketable securities totaled $295.6 million, down from $358.2 million at the end of 2024. The company stated these funds are expected to support planned operating expenses into 2028. Terns highlighted positive developments in its CARDINAL program, noting unprecedented Phase 1 efficacy data for TERN-701 in chronic myeloid leukemia and an upcoming expanded data presentation at ASH 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Terns Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9572752-en) on November 10, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2582008398"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582008398\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582008398?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-11 05:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582008398","market":"fut","top_or_hot":-1,"title":"Terns Pharmaceuticals posts Q3 net loss of $24.6 million on R&D spending increase","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Terns Pharmaceuticals posts Q3 net loss of $24.6 million on R&amp;D spending increase\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Terns Pharmaceuticals Inc. reported a net loss of $24.6 million for the third quarter ended September 30, 2025, compared to a net loss of $21.9 million for the same period in 2024. Research and development expenses increased to $19.9 million from $15.2 million, while general and administrative expenses decreased to $7.8 million from $9.8 million year-over-year. As of September 30, 2025, cash, cash equivalents, and marketable securities totaled $295.6 million, down from $358.2 million at the end of 2024. The company stated these funds are expected to support planned operating expenses into 2028. Terns highlighted positive developments in its CARDINAL program, noting unprecedented Phase 1 efficacy data for TERN-701 in chronic myeloid leukemia and an upcoming expanded data presentation at ASH 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Terns Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9572752-en) on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Terns Pharmaceuticals posts Q3 net loss of $24.6 million on R&D spending increase</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTerns Pharmaceuticals posts Q3 net loss of $24.6 million on R&D spending increase\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-11 05:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Terns Pharmaceuticals posts Q3 net loss of $24.6 million on R&amp;D spending increase\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Terns Pharmaceuticals Inc. reported a net loss of $24.6 million for the third quarter ended September 30, 2025, compared to a net loss of $21.9 million for the same period in 2024. Research and development expenses increased to $19.9 million from $15.2 million, while general and administrative expenses decreased to $7.8 million from $9.8 million year-over-year. As of September 30, 2025, cash, cash equivalents, and marketable securities totaled $295.6 million, down from $358.2 million at the end of 2024. The company stated these funds are expected to support planned operating expenses into 2028. Terns highlighted positive developments in its CARDINAL program, noting unprecedented Phase 1 efficacy data for TERN-701 in chronic myeloid leukemia and an upcoming expanded data presentation at ASH 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Terns Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9572752-en) on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDLbVd96T:1","article_id":"2582008398","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582008398","pubTimestamp":1762808729,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Terns Pharmaceuticals Inc. reported a net loss of $24.6 million for the third quarter ended September 30, 2025, compared to a net loss of $21.9 million for the same period in 2024. Research and development expenses increased to $19.9 million from $15.2 million, while general and administrative expenses decreased to $7.8 million from $9.8 million year-over-year. As of September 30, 2025, cash, cash equivalents, and marketable securities totaled $295.6 million, down from $358.2 million at the end of 2024. The company stated these funds are expected to support planned operating expenses into 2028. Terns highlighted positive developments in its CARDINAL program, noting unprecedented Phase 1 efficacy data for TERN-701 in chronic myeloid leukemia and an upcoming expanded data presentation at ASH 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","TERN":"Terns Pharmaceuticals, Inc."},"translate_title":"由于研发支出增加，Terns Pharmaceuticals第三季度净亏损2460万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TERN":0.9},"content_text":"Terns Pharmaceuticals posts Q3 net loss of $24.6 million on R&D spending increase\n    \n\n        Terns Pharmaceuticals Inc. reported a net loss of $24.6 million for the third quarter ended September 30, 2025, compared to a net loss of $21.9 million for the same period in 2024. Research and development expenses increased to $19.9 million from $15.2 million, while general and administrative expenses decreased to $7.8 million from $9.8 million year-over-year. As of September 30, 2025, cash, cash equivalents, and marketable securities totaled $295.6 million, down from $358.2 million at the end of 2024. The company stated these funds are expected to support planned operating expenses into 2028. Terns highlighted positive developments in its CARDINAL program, noting unprecedented Phase 1 efficacy data for TERN-701 in chronic myeloid leukemia and an upcoming expanded data presentation at ASH 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Terns Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9572752-en) on November 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}